Articles tagged with "Epidiolex"
11 total articles - Page 1 of 2
DEA loosens rules on prescription CBD drug EpidiolexDavid Downs - Published on April 6, 2020Read more
Prescription CBD tincture Epidiolex is coming to more patients. Cost: $32,500 per year.
FAQ: What to Know About the DEA’s CBD Rescheduling OrderBen Adlin - Published on September 28, 2018Read more
For one, it doesn’t actually reschedule CBD.
What’s Next for Epidiolex Maker GW PharmaceuticalsBen Adlin - Published on June 28, 2018Read more
Leafly spoke with VP Stephen Schultz about the significance of FDA approval, when Epidiolex might become available to patients, and what’s coming next from the drugmaker.
Why June 2018 Will Go Down as the Month Prohibition CrumbledBruce Barcott - Published on June 27, 2018Read more
Canada, Oklahoma, and the FDA: Here’s how each delivered a mortal blow to cannabis prohibition this month.
Is CBD Oil Legal Now? With Epidiolex Approved, It’s Still Not ClearBen Adlin - Published on June 25, 2018Read more
The FDA just approved the CBD drug Epidiolex. Here’s what that means for the legal status of CBD oil nationwide.
FDA Approves Epidiolex, a Marijuana-Based CBD Drug for SeizuresThe Associated Press - Published on June 25, 2018Read more
The Food and Drug Administration approved Epidiolex to treat two rare forms of epilepsy that begin in childhood. But it’s not quite medical marijuana.
Is FDA-Approved Cannabidiol a Blessing or Curse?The Associated Press - Published on June 19, 2018Read more
As the marijuana molecule cannabidiol nears FDA-approval, parents who for years have used cannabis to treat severe forms of epilepsy in their children are feeling more cautious than celebratory.
Study Finds CBD Drug Epidiolex Reduces Seizures by 42%Ryan Basen - Published on May 16, 2018Read more
High daily doses of CBD significantly reduced seizures in patients with Lennox-Gastaut syndrome.
GW Pharma Responds: ‘Not Creating a Monopoly’Bruce Barcott - Published on February 22, 2017Read more
The pharmaceutical developer says it’s pioneering markets, not elbowing out competitors.
Leafly Exclusive: GW Pharma Is Moving CBD Bills on the Down LowBruce Barcott - Published on February 17, 2017Read more
The proposed state measures would give the British pharma company’s new drug–but not other CBD products–legal status.